Skip to main content
SpringerLink
Log in

Immunopathological features of human pulmonary tumors following low-dose interleukin-2

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

We administered preoperative low-dose interleukin-2 (IL-2) to 10 patients undergoing thoracotomy for pulmonary tumors. The in vivo effect of IL-2 on tumor-associated lymphocyte activity was assessed in the resected specimens by immunohistochemistry and compared with observations in 45 patients who did not receive IL-2. H & E evaluation revealed an increase in intra- and peritumoral lymphocyte infiltration in the IL-2-treated patients. Immunopathological evaluation with monoclonal antibodies revealed that this lymphocyte infiltration was predominantly CD5-positive T cells. The amount of intra-and peritumoral lymphocyte activity correlated with the dose of IL-2 administered (6000–90 000 international units/kg every 8 h for 48 h. IL-2-treated patients showed increases in T-cell-associated activation markers (IL-2 α-receptor, transferrin receptor and HLA-DR) on peritumoral lymphocytes, but not on intratumoral lymphocytes. We previously reported that low-dose IL-2 increases the intrinsic natural killer cell cytotoxicity of intratumoral lymphocytes and suggest that this lymphocyte infiltration is further evidence that low-dose IL-2 can augment in vivo lymphocyte activity at the tumor site.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Agah R, Malloy B, Sherrod A, Mazunder A (1988) Successful therapy of natural killer-resistant pulmonary metastases by the synergism of γ-interferon with tumor necrosis factor and interleukin-2 in mice. Cancer Res 48: 2245

    Google Scholar 

  2. Anderson TM, Ibayashi Y, Tokuda Y, Colquhoun SD, Holmes EC, Golub SH (1988) Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. Cancer Res 48: 1180

    Google Scholar 

  3. Anzano MA, Roberts AB, Smit MB, Sporn MB, DeLaco JE (1983) Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type a and type b transforming growth factors. Proc Natl Acad Sci USA 80: 6264

    Google Scholar 

  4. Cameron RB, McIntosh JK, Rosenberg SA (1988) Synergistic antitumor effects of combination immunotherapy with recombinant hybrid α-interferon in their treatment of established murine hepatic metastases. Cancer Res 48: 5810

    Google Scholar 

  5. Cochran AJ (1969) Histology and prognosis in malignant melanoma. J Pathol 97: 459

    Google Scholar 

  6. Cohen PJ, Lotze MT, Roberts JR, Rosenberg SA, Jaffe ES (1987) The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol 129: 208

    Google Scholar 

  7. Cotner T, Williams JM, Christenson L, Shapiro HM, Strom TB, Strominger J (1983) Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med 157: 461

    Google Scholar 

  8. Crump WL, Owen-Schaub LB, Grimm EA (1989) Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells. Cancer Res 49: 149

    Google Scholar 

  9. Ebert EC, Brolin RE, Roberts AI (1989) Characterization of activated lymphocytes in colon cancer. Clin Immunol Immunopathol 50: 72

    Google Scholar 

  10. Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalaian SL, Yang JC, Yolles P, Larson SM, Rosenberg SA (1989) Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7: 250

    Google Scholar 

  11. Funkhouser WK, Neckers LM, Ames RS, Carney DN, Roth JA (1986) Inhibition of DNA synthesis by a small-cell lung carcinoma-derived protein. JNCI 77: 925

    Google Scholar 

  12. Grimm EA, Crump WL, Durett A, Hester JP, Lagoo-Deenadalayan S, Owen-Schaub LB (1988) TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol Immunother 27: 53

    Google Scholar 

  13. Guesdon J-L, Ternynek T, Avrameas S (1979) The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 27: 1131

    Google Scholar 

  14. Hamlin IME (1968) Possible host resistance in carcinoma of the breast: a histological study. Br J Cancer 22: 383

    Google Scholar 

  15. Hoon DS, Irie RF, Cochran AJ (1988) Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2. Cell Immunol 111: 410

    Google Scholar 

  16. Kikuchi K, Neuwelt EA (1983) Presence of immunosuppressive factors in brain tumor cyst fluid. J Neurosurg 59: 790

    Google Scholar 

  17. Kradin RL, Boyle LA, Preffer FI, Callahan RJ, Barlai-Kovach M, Strauss HW, Subinett S, Kurnick JT (1987) Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother 24: 76

    Google Scholar 

  18. Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ, Strauss HW (1989) Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1: 577

    Google Scholar 

  19. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA (1985) In vivo administration of purified human interleukin 2: II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135: 2865

    Google Scholar 

  20. Lotze MT, Custer MC, Rosenberg SA (1986) Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg 121: 1373

    Google Scholar 

  21. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 256: 3117

    Google Scholar 

  22. McIntosh JK, Mule JJ, Merino MJ, Rosenberg SA (1988) Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-α. Cancer Res 48: 4011

    Google Scholar 

  23. Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 6: 409

    Google Scholar 

  24. Moy PM, Holmes EC, Golub SH. A method for improved yield and purity in extracting lymphocytes from lung tumors (1985) J Surg Res 38: 17

    Google Scholar 

  25. Mulé JJ, Shu S, Schwarz SL. Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487

    Google Scholar 

  26. Neckers LM, Cossman J (1983) Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin-2. Proc Natl Acad Sci USA 80: 3494

    Google Scholar 

  27. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS (1981) Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells: IX. The quantitation of natural killer cell activity. J Clin Immunol 1: 51

    Google Scholar 

  28. Ramsdell FJ, Golub SH (1987) Generation of lymphokine-activated killer cell activity from human thymocytes. J Immunol 139: 1446

    Google Scholar 

  29. Robinson BWS, Kees UR, Holt PG (1989) Lung intersitial natural killer cells in patients with lung cancer: presence, activity and response to interleukin-2. Lung Cancer 5: 41

    Google Scholar 

  30. Rosenberg SA, Lotze MT, Muul LM. Lettman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485

    Google Scholar 

  31. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318

    Google Scholar 

  32. Rosenberg SA, Packard BS, Aebersold PM, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676

    Google Scholar 

  33. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474

    Google Scholar 

  34. Roth JA, Grimm EA, Gupta RK, Ames RS (1982) Immunoregulatory factors associated with human tumors, immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vivo. J Immunol 178: 1955

    Google Scholar 

  35. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT (1989) Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 49: 7086

    Google Scholar 

  36. Shau H, Shen D, Golub SH (1986) The role of transferrin in natural killer cell and IL-2-induced cytotoxic cell function. Cell Immunol 97: 121

    Google Scholar 

  37. Shau H, Gray JD, Golub SH (1988) Studies on cytotoxicity generated in human mixed lymphocyte culture: IV. Interleukin-2 alone or from mixed lymphocyte culture yields natural killer-like cytotoxic cells distinct from allospecific cytotoxic T lymphocytes. Cancer Immunol Immunother 27: 255

    Google Scholar 

  38. Shimokawara I, Imamura M, Yamanaka N, Ishii Y, Kikuchi K (1982) Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: an immunoperoxidase study with anti-human T- and B-cell sera. Cancer 49: 1456

    Google Scholar 

  39. Tokuda Y, Ebina N, Golub SH (1989) The inhibitory effect of human interferon α on the generation of lymphokine-activated killer activity. Cancer Immunol Immunother 30: 205

    Google Scholar 

  40. Underwood JCE (1974) Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer 30: 538

    Google Scholar 

  41. Warnke R, Levy R (1980) Detection of T and B cell antigens with hybridoma monoclonal antibodies. J Histochem Cytochem 28: 771

    Google Scholar 

  42. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Surgical Oncology, John Wayne Cancer Clinic, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, 9-267 Louis Factor Building, 90 024, Los Angeles, CA, USA

    Stephen G. Swisher, Timothy M. Anderson, Duan-Ren Wen, Mark A. Stene, Alistair J. Cochran, Sidney H. Golub & E. Carmack Holmes

Authors
  1. Stephen G. Swisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy M. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Duan-Ren Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark A. Stene
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alistair J. Cochran
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sidney H. Golub
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Carmack Holmes
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported in part by USPHS grants CA 44 352 (S. H. G.) and 43 658 (A. J. C.). S. G. S. was supported by NIH Surgical Oncology Training Grant CA 09 010

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swisher, S.G., Anderson, T.M., Wen, DR. et al. Immunopathological features of human pulmonary tumors following low-dose interleukin-2. Cancer Immunol Immunother 33, 327–332 (1991). https://doi.org/10.1007/BF01756598

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01756598

Key words

Search

Navigation